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The generation of Ab, the main component of senile
plaques in Alzheimer’s disease (AD), is precluded
by a-secretase cleavage within the Ab domain of
the amyloid precursor protein (APP). We identified
two rare mutations (Q170H and R181G) in the prodo-
main of the metalloprotease, ADAM10, that cosegre-
gate with late-onset AD (LOAD). Here, we addressed
the pathogenicity of these mutations in transgenic
mice expressing human ADAM10 in brain. In
Tg2576 ADmice, bothmutations attenuated a-secre-
tase activity of ADAM10 and shifted APP processing
toward b-secretase-mediated cleavage, while en-
hancing Ab plaque load and reactive gliosis. We
also demonstrated ADAM10 expression potentiates
adult hippocampal neurogenesis, which is reduced
by the LOAD mutations. Mechanistically, both
LOAD mutations impaired the molecular chaperone
activity of ADAM10 prodomain. Collectively, these
findings suggest that diminished a-secretase activ-
ity, owing to LOAD ADAM10 prodomain mutations,
leads to AD-related pathology, strongly supporting
ADAM10 as a promising therapeutic target for this
devastating disease.
INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia
in the elderly, with more than five million patients in the U.S.
alone. The greatest known risk factor for AD is advanced age,
with incidence doubling every decade after 60 years of age.
The second greatest risk factor for AD is family history. Heritabil-
ity for AD is estimated to be as high as 80% (Gatz et al., 2006).
Early-onset familial AD (EO-FAD) can be caused by fully pene-
trant mutations in three genes, APP and the two presenilins
(PSEN1 and PSEN2). The most well-established late-onset AD
(LOAD) gene is apolipoprotein E (APOE), in which the ε4 variant
increases risk by 3.7-fold (one copy) to >10-fold (two copies)
(Bertram et al., 2010). AD is characterized by the cerebralneuronal loss and deposition of amyloid-b protein (Ab) in senile
plaques. Vast amounts of clinical and biochemical data, in addi-
tion to the four established AD genes, support the hypothesis
that abnormal processing of APP and the accumulation of its
metabolite, Ab, play key roles in the etiology and pathogenesis
of AD (Hardy and Selkoe, 2002).
APP is a type one transmembrane protein that can be pro-
cessed into a variety of proteolytic fragments. Ab, a 4-kDa-sized
fragment, is generated via serial cleavage of APP by b-secretase
(BACE1) at ectodomain and g-secretase at intramembranous
sites. In contrast, cleavage of APP at the juxtamembrane by
a-secretase precludes Ab generation. a- versus b-secretase
cleavage of APP may also lead to different functional conse-
quences. The secreted APP ectodomain generated by a-secre-
tase, sAPPa, has neurotrophic and neuroprotective properties
in vivo and in vitro (Mattson et al., 1993; Ring et al., 2007). In
contrast, the b-secretase-derived product sAPPb is not as neu-
roprotective, and upon further processing, can render proapo-
ptotic and neurodegenerative effects on neuronal cells (Nikolaev
et al., 2009). Several members of the ADAM (a disintegrin and
metalloprotease) family proteases, including ADAM9, ADAM10,
and ADAM17, have been reported to possess a-secretase activ-
ity at least under in vitro conditions. However, recent evidence
indicates that ADAM10 is the major a-secretase responsible
for the ectodomain shedding of APP in themouse brain (Jorissen
et al., 2010; Kuhn et al., 2010; Postina et al., 2004).
Nascent ADAM10 is produced as a zymogen andmatures into
an active protease only after the liberation of its prodomain by
furin or proconvertase 7 in the trans-Golgi secretory pathway
(Lammich et al., 1999). After maturation, the majority of the
ADAM10 is transported to the plasma membrane, where it acts
as a sheddase for cell surface proteins, such as APP. Recent
studies have shown that ADAM10 itself is also subject to shed-
ding in cultured cells (Parkin and Harris, 2009; Tousseyn et al.,
2009). Numerous studies ofmetalloprotease family proteins sug-
gest that the prodomain of ADAM10 plays critical roles in the
maturation of the enzyme. The primary function of the prodomain
is to keep the ADAM10 zymogen in an inactive status via direct
interaction with the catalytic site (Moss et al., 2007), thereby pre-
venting autocatalysis during biosynthesis. Another function of
the prodomain is to serve as an intramolecular chaperone, facil-
itating the proper folding of other domains of the protein (Cao
et al., 2000; Shinde et al., 1997). While recombinant ADAM10Neuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc. 385
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tive, coexpression of the prodomain in trans has been shown to
restore the a-secretase activity of the enzyme (Anders et al.,
2001).
In addition to function as a major a-secretase for APP,
ADAM10 plays an essential role in embryonic neurogenesis
and brain development (Jorissen et al., 2010; Pan and Rubin,
1997). Both ADAM10 knockout (KO) and conditional KO mice
are lethal in early developmental stages (Hartmann et al., 2002;
Jorissen et al., 2010), potentially due to the lack of ectodomain
shedding of Notch and its ligands by ADAM10. Recent studies
have shown that neurogenesis in adult hippocampus plays an
essential role in learning and memory (Zhao et al., 2008).
Whether ADAM10 plays a role in adult hippocampal neurogene-
sis has yet to be addressed.
To assess the candidacy of ADAM10 as a LOAD susceptibility
gene, we previously genotyped 30 SNPs that span the gene to
test for genetic association with AD. These analyses, followed
by targeted resequencing of ADAM10, ultimately led to the iden-
tification of two nonsynonymous mutations, Q170H and R181G,
in seven LOAD families (Kim et al., 2009). Overexpression of both
mutant forms of ADAM10 in cell cultures significantly increased
Ab levels as compared to wild-type (WT) ADAM10 controls
(Kim et al., 2009). Here, we set out to demonstrate the pathoge-
nicity of the two ADAM10 mutations in transgenic mouse
models. For this purpose, we generated transgenic mice that ex-
press either WT or LOAD mutant forms of human ADAM10 and
compared the differences in APP processing among the multiple
lines of WT andmutant transgenic mice expressing similar levels
of ADAM10 in brain. The impact of the mutations on Ab accumu-
lation and plaque deposition was further assessed by crossing
these ADAM10 transgenic mice with Tg2576 mice, a well-char-
acterized AD mouse model that overexpresses human APP
Swedish mutation (APPswe) and is known to cause an APP
ectodomain cleavage shift that favors the b- over the a-site.
We also assessed the effect of the LOADmutations on adult hip-
pocampal neurogenesis and, finally, we explored the underlying
molecular mechanisms by which the LOAD mutations in the
ADAM10 prodomain attenuate a-secretase activity.
RESULTS
The ADAM10 Prodomain Mutations Attenuate
Ectodomain Shedding of ADAM10
To test the in vivo effects of the two LOAD-associated ADAM10
mutations on a-secretase activity, we generated transgenicmice
overexpressing human WT ADAM10, ADAM10 harboring the
LOAD-associated mutations Q170H or R181G, and an artificial
dominant-negative (DN) mutation, E384A. All transgenes were
driven by the mouse prion protein promoter (MoPrP) and tagged
with hemagglutinin (HA) at the C terminus of the protein (Figures
S1A and S1B available online). For each ADAM10 genotype, we
obtained three WT, three Q170H, eight R181G, and three DN F1
transgenic mice, which were bred with nontransgenic littermates
to maintain mouse lines. The brains from F2 and F3 progenies of
each line were analyzed for ADAM10 expression and APP pro-
cessing. Western blot analysis of 12-week-old mouse brains re-
vealed that a WT transgenic line (WT-58) expressed 2.5-fold386 Neuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc.higher level of mature ADAM10 in brain than nontransgenic con-
trol (Figure S1C). In addition to the pro and mature forms of
ADAM10, high levels of ADAM10-CTF (10 kDa) were detected
in the membrane fraction (Figures 1A–1C and S1D). Previous
studies have shown that these ADAM10-CTFs are generated
by ectodomain shedding of ADAM10 mature forms (Parkin and
Harris, 2009; Tousseyn et al., 2009). Interestingly, as compared
to the ADAM10-WT transgenic mice, the levels of ADAM10-
CTF were significantly reduced in mice expressing either of the
two LOAD mutations and were undetectable in mice expressing
DN mutation (Figures 1A and 1C). This pattern of reduced
ADAM10-CTF was consistently observed in all the ADAM10
LOAD and DN mutant lines as compared to WT transgenic lines
(two WT, three Q170H, six R181G, and three DN ADAM10 trans-
genic lines) and in the three single F1 mice (one WT and two
R181G, which failed to produce progeny). The decrease in
ADAM10-CTF generation was also detected in primary cortical
neurons derived from the LOADmutant mice (Figure S1E). These
results indicate that both the LOAD and DN ADAM10 mutations
decreased ectodomain shedding of the metalloprotease.
Consistent with our findings, previous studies have shown that
artificial mutations at the prodomain cleavage or catalytic sites,
which block enzyme activity of the corresponding ADAM prote-
ases (ADAM13 and ADAM19), also result in the prevention of its
own ectodomain shedding at their cysteine-rich domains
(Gaultier et al., 2002; Kang et al., 2002).
In vitro studies have previously suggested that ectodomain
shedding of ADAM10 depends on the activity of ADAM family
proteins, including ADAM9 and ADAM17 (Parkin and Harris,
2009; Tousseyn et al., 2009). Conversely, ADAM10 activity was
found to be essential for the ADAM9 function (Taylor et al.,
2009). To further investigate the ectodomain shedding of
ADAM10, we assessed the expression and processing of endog-
enous ADAM9 in each genotype of ADAM10 transgenic mice.
Levels of pro and mature ADAM9 and ADAM9-CTF were unaf-
fected by the expression of WT or mutant forms of ADAM10 (Fig-
ure S1F). In addition, overexpression of ADAM10-DN did not
interfere with the generation of ADAM10-CTF from either trans-
genic or endogenous ADAM10 proteins (Figure S1G). Taken
together, these results suggest that the decrease in ADAM10-
CTF levels observed in mice expressing LOAD mutations is
due to the reduced autoproteolytic activity of the mutant
ADAM10. A reduced ratio of pro versus mature ADAM10 in the
Q170H mutant lines suggested that the mutation might also
affect the liberation of its prodomain (Figure S1H). However,
the marked variability of the ratio of pro versus mature
ADAM10 in mice expressing the other ADAM10 mutations,
R181G and DN, indicates that ADAM10 prodomain cleavage
does not depend on the enzyme activity of the metalloprotease.
Expression of ADAM10 LOAD Prodomain Mutations
Attenuates Nonamyloidogenic Processing of
Endogenous Mouse APP
To examine the effect of the LOAD ADAM10 mutations on
endogenous APP processing, we selected two mouse lines
from each of the four genotypes, expressing comparable levels
of mature ADAM10 (Figures 1A and 1B), and analyzed the levels
of APP and its cleavage products in the brain. Compared to
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Figure 1. Effect of ADAM10 LOAD Prodomain Mutations on ADAM10 Ectodomain Shedding and APP Processing in Brain
(A) Representative western blot images for ADAM10 expression and APP processing in 12-week-old mouse brains. Anti-HA and anti-APP C-terminal antibody
(A8717) were used to detect full-length andCTF forms of ADAM10 and APP, respectively, in RIPA buffer-soluble total brain lysates. TBS-soluble fraction was used
to detect sAPP (22C11, anti-APP N terminus), sAPPa, and sAPPb. Arrowhead indicates C-terminal truncated sAPP. *, nonspecific band.
(B–G) Densitometric quantification of western blot results of two mouse lines each from the four different genotypes. Number in parenthesis denotes the number
of mice analyzed. Relative value of 100 is given for WT-58 mouse line for mature ADAM10 (B) and ADAM10-CTF (C). Relative value of 100 is given for non-
transgenic mouse for the analysis of APP processing products, mature APP (D), APP-CTFa (E), sAPPa (F), and sAPPb (G). Values aremean ± SEM. *p < 0.05, **p <
0.01, ***p < 0.001 versus WT-58 mouse line (t test). See also Figure S1.
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ADAM10 Mutations Increase b-Amyloid Accumulationnontransgenic control, ADAM10 WT transgenic mice exhibited
lower levels of mature APP and sAPPb and higher levels of
APP-CTFa and sAPPa (Figures 1A and 1D–1G). Mature APP is
cleaved primarily by a-secretase at the cell surface into APP-
CTFa and sAPPa, and accumulating evidence supports thatAPP is cleaved competitively by a- and b-secretase in neural
cells (Colombo et al., 2012; Lee et al., 2005; Postina et al.,
2004). Thus, overexpression of ADAM10-WT increased a-secre-
tase cleavage while decreasing b-secretase cleavage of endog-
enous APP. In contrast, expression of ADAM10-DN had anNeuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc. 387
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ADAM10 Mutations Increase b-Amyloid Accumulationopposite effect on APP processing. Compared to the WT trans-
genic controls, both Q170H and R181G mutant transgenic mice
exhibited significant attenuation of APP processing, i.e., less of
an increase in APP-CTFa levels and less of a decrease in mature
APP and sAPPb levels. Interestingly, however, the level of sAPPa
in the two LOAD mutant mice was not reduced when compared
to that of ADAM10-WTmice (Figures 1A and 1F). This is likely due
to the enhanced degradation of sAPPa in the brains expressing
ADAM10-WT over the other mutant forms. In support of this hy-
pothesis, we observed higher levels of 70 kDa sAPP degrada-
tion products in the brains of ADAM10-WT as compared to the
two LOAD mutant mice (Figure 1A). Moreover, compared to
the nontransgenic control, the amount of total sAPP was barely
different in ADAM10 transgenic mice expressing either WT or
any mutant forms. These data suggest a presence of a potential
compensatory mechanism that maintains the total level of sAPP
in the brain regardless of ADAM10 expression levels. We also
measured the levels of secreted APP (sAPPa, sAPPb, and total
sAPP) in cerebrospinal fluid (CSF) and found similar patterns
depending on the ADAM10 genotypes (Figure S2A). Levels of
endogenous Ab40 and Ab42 (measured by ELISA) were signifi-
cantly lower in ADAM10-WT mice compared to the nontrans-
genic controls, while the levels were dramatically higher in
ADAM10-DN mice (Figure S2B). For mice expressing either
Q170H or R181G mutations, a trend was observed in which
endogenous Ab levels were increased compared to ADAM10-
WT mice. Taken together, these data reveal that both ADAM10
LOAD prodomain mutations attenuate but do not entirely abolish
a-secretase activity of ADAM10 on APP.
Next, we asked whether the prodomain mutations affect the
cleavage of other ADAM10 substrates besides APP (Pruess-
meyer and Ludwig, 2009).We examined the processing of candi-
date ADAM10 substrates in the brain including APLP2, Notch1,
and N-cadherin. The processing of APLP2 showed very similar
patterns to those of APP in that ADAM10-WT overexpression
resulted in the increased cleavage of mature APLP2, while this
was attenuated in mice expressing either of the two LOAD
mutations (Figure S2C). Interestingly, 57-kDa-sized C termi-
nus-truncated soluble APLP2, analogous to the soluble APP
cleavage product, was detected more abundantly in ADAM10-
WT than the LOAD mutant mouse brains. In contrast, western
blot analysis of adult brains and primary neurons derived from
ADAM10 transgenic mice showed ADAM10 overexpression
barely affected N-cadherin level or N-cadherin-CTF generation
(Figure S2D). In contrast to embryonic brains, most of
Notch1 protein in adult brains is cleaved and present as
extracellular truncated forms in the membrane. We found that
neither WT nor mutant ADAM10 overexpression changed the
level of full-length or truncated forms of Notch1 (Figure S2E).
Together, these data suggest that the processing of APP family
proteins is particularly vulnerable to loss-of-functionmutations in
ADAM10.
LOAD ADAM10 Mutations Increase Amyloidogenic
Processing of APP and Ab Levels in Tg2576/ADAM10
Double-Transgenic Mouse Brains
To evaluate the effects of the two LOAD ADAM10 mutations on
AD pathogenesis, we crossed transgenic mice expressing WT388 Neuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc.or mutant forms of ADAM10 with Tg2576 ADmice and assessed
APP processing, Ab levels, and amyloid plaque load. As in the
ADAM10 transgenic mice, the prion protein promoter was uti-
lized in the Tg2576 mice to express human APPswe. Western
blot analysis of mouse brain lysates revealed that APP expres-
sion was several-fold higher in Tg2576 mice than in nontrans-
genic control. However, ADAM10 expression in Tg2576/
ADAM10 double-transgenic mice was maintained at similar
levels to those in parental ADAM10 single-transgenic mice (Fig-
ures 2A and S3A). Attenuation of a-secretase activity by the
LOAD mutations was clearly evident in the mutant Tg2576/
ADAM10 double-transgenic mice. Compared to the double-
transgenic mice expressing ADAM10-WT (Tg2576/WT), the
decrease of mature APP and increase of APP-CTFa were signif-
icantly reduced in 3-month-old brains expressing either Q170H
(Tg2576/Q170H) or R181G (Tg2576/R181G) ADAM10 mutations
(Figures 2A and 2B). Moreover, the levels of sAPPb and APP-
CTFb were elevated by both LOAD mutations in comparison to
Tg2576/WT mice. Quantitative analysis of brain sAPPa and
sAPPb by ELISA revealed similar patterns as compared to the
results from western blots (Figure 2C). The ratios of both APP-
CTFa:APP-CTFb and sAPPa:sAPPb indicate that both the
LOAD mutations shifted more than 50% of the APP processing
from the a-secretase to b-secretase pathway. While the ratio
of a- versus b-cleavage was still higher in Tg2576/Q170H and
Tg2576/R181G mice than Tg2576, the DN mutation modestly
shifted APP processing toward b-cleavage. However, the in-
crease in b-secretase cleavage of APP by mutant ADAM10
expression was not caused by altered BACE1 expression (Fig-
ure 2A). Notably, as observed in the ADAM10 single-transgenic
mice, no differences were found in sAPPa levels among
Tg2576/WT, Tg2576/Q170H, and Tg2576/R181G double-trans-
genic mice (Figures 2A and 2B). Instead, C-terminal truncated
sAPP were detected more abundantly in mice expressing the
WT form (Figures 2A, S3B, and S3C). Given the robust increase
of APP-CTFa and concurrent decrease of APP-CTFb by
ADAM10-WT expression, the C terminus truncated sAPP are
probably generated from sAPPa.
Next, we examined Ab levels in the Tg2576/ADAM10 double-
transgenic mice. In the brains of 3-month-old Tg2576/WT
mice, both TBS-soluble Ab40 and Ab42 levels were reduced
35% compared to Tg2576 control (Figure 3A). However, the
ADAM10-mediated decrease in Ab40 and Ab42 was significantly
attenuated in both Tg2576/Q170H and Tg2576/R181G mice.
Tg2576/DN mice exhibited higher Ab levels than Tg2576 alone,
which indicates decreased nonamyloidogenic processing of
APP in the presence of the DN form. In 3-month-old brains,
TBS-insoluble Ab was barely detectable in Tg2576 or Tg2576/
ADAM10 mice (data not shown). As the deposition of insoluble
Ab occurs at 7–8 months in the brains of Tg2576 mice (Kawara-
bayashi et al., 2001), the total Ab levels at 12 months were
hundreds-fold higher than those at 3 months (Figure 3B). Corre-
spondingly, in 12-month-old mice, the reduction of Ab levels in
Tg2576/WT was dramatically amplified in both TBS-soluble
(>90%) and insoluble (>99%) Ab fractions (Figure 3B). Compared
to the Tg2576/WT, there was much less of a decrease in Ab
levels in Tg2576/Q170H mice. However, Tg2576/Q170H mice
also showed a robust decrease in brain Ab levels as compared
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Figure 2. Impact of ADAM10 LOAD Prodomain Mutations on Nonamyloidogenic Processing of APP in Tg2576/ADAM10 Double-
Transgenic Mice
(A) APP processing in the brains of 3-month-old Tg2576/ADAM10 double-transgenic mice. Endogenous mouse sAPPa was barely detected by the 6E10 anti-
body, the epitope for which is based on human APP. Arrowhead indicates C-terminal truncated sAPP. *, nonspecific band.
(B) Densitometric analysis of APP-CTFa, APP-CTFb, sAPPa, and sAPPb and ratios of CTFa:CTFb and sAPPa:sAPPb. Analyzed mice number: Tg2576 (n = 6),
Tg2576/WT (5), Tg2576/170 (5), Tg2576/181 (4), Tg2576/DN (5). *p < 0.05, **p < 0.01, ***p < 0.001 versus Tg2576/WT (t test).
(C) ELISA for sAPPa and sAPPb levels in TBS-soluble brain lysates. Analyzed mice number: Tg2576 (n = 10), Tg2576/WT (5), Tg2576/170 (5), Tg2576/181, (5)
Tg2576/DN (5). *p < 0.05, **p < 0.01, ***p < 0.001 versus Tg2576/WT; ###p < 0.001 versus Tg2576 (one-way ANOVA and Tukey’s test). Values are mean ± SEM.
See also Figure S2.
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ADAM10 Mutations Increase b-Amyloid Accumulationto Tg2576. This decrease was most likely due to partial, but not
complete, loss of a-secretase activity by the LOAD mutation.
Combined with endogenous ADAM10, transgenic mice overex-
pressing the LOAD mutation still had overall higher a-secretase
activity than ADAM10 nontransgenic control (Figures 1 and 2).
The decrease in Ab levels by ADAM10-WT or -Q170H overex-
pression was also confirmed by western blot analysis of 12-
month-old AD mouse brain (Figure 3C). The Tg2576/R181G
mice were examined only in small numbers (n < 3) at 12 months
of age, due to the similarities noted in the patterns of APP pro-
cessing and Ab generationwith Tg2576/Q170Hmice at 3months
of age (Figure 2A and 2B). These mice also exhibited an increase
in Ab levels as compared to the Tg2576/WT (data not shown).
Other APP cleavage fragments remained at similar levels
between 3 and 12 months old (Figures 2A and S3D). Thus, the
enhanced impact of ADAM10 on cerebral Ab amount at
12 months, compared to 3 months, might be the result of accu-
mulated effect of APP processing change (amyloidogenic versusnonamyloidogenic) and Ab deposition over the several months
time period.
We did not detect changes in the ratio of Ab40 and Ab42 in
brains expressing either WT or mutant forms of ADAM10 (Fig-
ure 3A, 3B, and S2B). This suggests that the change in
ADAM10 activity did not affect the preference of g-secretase
cleavage site in APP-CTFb. Most early-onset familial AD muta-
tions in APP, PSEN1, and PSEN2 increase the Ab42/Ab40 ratio,
with a few exceptions (e.g., APP Swedish and APP duplication
mutations), which increase total Ab levels. Our results indicate
that the ADAM10 LOAD mutations elevate both Ab40 and Ab42
levels in the brain, without affecting the Ab42/Abb40 ratio.
ADAM10 Activity Regulates Ab Plaque Load and
Morphology, and Reactive Gliosis in AD Mouse Brain
Immunofluorescence staining of 12-month-old brain sections
with anti-Ab antibodies revealed notable amounts of Ab plaques
in Tg2576mice (Figures 4A and 4B). However, virtually no plaqueNeuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc. 389
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Figure 3. Increased Ab40 and Ab42 Levels in AD Mice Expressing the ADAM10 LOAD Prodomain Mutations
(A and B) TBS buffer-soluble and insoluble Ab40 and Ab42 levels were measured for 3- (A) and12-month-old (B) Tg2576 single or Tg2576/ADAM10 double-
transgenic mice by sandwich ELISA. Analyzed mice number, 3-month-old groups: Tg2576 (n = 4 male and 4 female), Tg2576/WT (3M, 2F), Tg2576/170 (2M, 3F),
Tg2576/181 (3M, 2F), Tg2576/DN (2M, 3F); 12-month-old groups: Tg2576 (4M, 4F), Tg2576/WT (3M, 2F), Tg2576/170 (3M, 3F), Tg2576/DN (3M, 3F). *p < 0.05,
**p < 0.01 versus Tg2576/WT; #p < 0.05 versus Tg2576 (t test). Breaks are inserted to adjust different scales in graphs for Ab level in 12-month-old brains. Values
are mean ± SEM.
(C) WB analysis of detergent (RIPA)-soluble total brain lysates from 12-month-old mice using 16% Tricine gel with 6E10 antibody. The human APP, sAPPa, APP-
CTFb, and Ab were detected in the immunoblot by 6E10. *, nonspecific band. WB analysis for TBS-buffer insoluble, but formic acid-soluble, fraction produced
similar results (data not shown). See also Figure S3.
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ADAM10 Mutations Increase b-Amyloid Accumulationwas detected in Tg2576/WT brain sections. Compared to
Tg2576, reduced Ab plaque counts in Tg2576/Q170H mouse
brains indicate the prodomain mutation diminished but did390 Neuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc.not abolish the a-secretase (anti-amyloidogenic) activity of
ADAM10. In contrast, both Ab levels and plaque counts were
elevated in Tg2576/DN (compared to Tg2576 mice), suggesting
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Figure 4. Effect of WT and Mutant Forms of ADAM10 Expression on Ab Plaque Load in AD Mice
(A) Ab plaques were detected by anti-Ab antibodies (red) in 12-month-old (first row, cortex) and 20-month-old (second and fourth rows, cortex/hippocampus)
Tg2576 single or Tg2576/ADAM10 double-transgenic mice. Dense neuritic plaques were stained by Thioflavin S (green, third and fourth rows). Large and small
arrows indicate neuritic and diffuse plaques, respectively. DAPI (blue) was used for nuclei counterstaining. Scale bar represents 100 mm.
(B) Counts of total Ab plaque numbers in 12-month-old mice (6–12 sections/mouse). Red: plaque size >50 mm, blue: <50 mm. Analyzed mice number: Tg2576
(n = 4M, 4F), Tg2576/WT (3M, 2F), Tg2576/170 (3M, 3F), Tg2576/DN (3M, 3F). *p < 0.05, **p < 0.01 (t test).
(C) Ab plaque load in the cortex and hippocampus of 18- to 20-month-old Tg2576/ADAM10 mice. Analyzed mice number: Tg2576 (n = 5M, 5F), Tg2576/WT
(2M, 2F), Tg2576/170 (2M, 3F), Tg2576/DN (3M, 3F). *p < 0.05, **p < 0.01, ***p < 0.001 (t test).
(D) Brain sections of Tg2576/170 (top) and Tg2576/DN (bottom) mice were immunolabeled with 3D6 Ab antibody followed by staining with Thioflavin S.
(E) Counts of Thioflavin S-stained plaque in 18- to 20-month-old mice. ***p < 0.001 (t test). Values are mean ± SEM.
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Figure 5. Effect of ADAM10 on Gliosis in AD
Mouse Brains
(A) Photomicrographs of 20-month-old Tg2576/
ADAM10 mouse cortex immunolabeled with Iba1
(brown), a microglial marker, and Congo red
(orange). Arrows indicate Congo red-stained
neuritic plaques. High magnification (bottom) of
Iba1 staining showed the high density of activated
microglia around neuritic plaques. Scale bar
represents 100 mm.
(B) Percentile of Iba1-immunoreactive area in
cortex. Analyzed mice number for Iba1 and
GFAP immunostaining: Tg2576 (n = 5M, 5F),
Tg2576/WT (2M, 2F), Tg2576/170 (2M, 3F),
Tg2576/DN (3M, 3F). *p < 0.05, **p < 0.01, ***p <
0.001 (t test).
(C) Photomicrographs of Tg2576/ADAM10 mouse
cortex stained with an astrocyte marker, GFAP.
Arrows indicate Congo red-stained neuritic
plaques. High magnification (bottom) of GFAP
staining revealed hypertrophy of astrocyte
around neuritic plaques. Scale bar represents
100 mm.
(D) Percentile of GFAP-immunoreactive area in
cortex. *p < 0.05, **p < 0.01, ***p < 0.001 (t test).
Values are mean ± SEM. See also Figure S4.
Neuron
ADAM10 Mutations Increase b-Amyloid Accumulationthat ADAM10-DN expression downregulates a-secretase activ-
ity of endogenous mouse ADAM10. In 18- to 20-month-old
brains, Ab plaque loads were markedly increased in Tg2576
and Tg2576/DN, whereas small numbers of only tiny plaques
were observed in Tg2576/WT mice (Figures 4A and 4C). The
differences in plaque load among the four groups remained
consistent up to the 18- to 20-month-old time point (Figures
4B and 4C).
Interestingly, in addition to this dramatic difference in Ab
plaque load, the morphology of plaque was also affected by
ADAM10 activity. Tg2576 mice at this age have both neuritic
and diffuse plaques (Figure 4A) (Kawarabayashi et al., 2001).
Costaining with Thioflavin S and anti-Ab antibody (3D6) showed
that core-containing neuritic plaques (Thioflavin S-positive)392 Neuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc.were more predominant in Tg2576/DN
than in Tg2576 brains (Figures 4A and
4E). On the contrary, most Ab aggre-
gates in Tg2576/Q170H or Tg2576/
WT mice were diffuse plaques (Thioflavin
S-negative). Overall, the ratio of
neuritic versus diffuse plaque is inversely
correlated with ADAM10 activity in
Tg2576/ADAM10 mice. This relation-
ship is more evident when plaque
morphology is compared between 12-
month-old Tg2576/DN and 20-month-
old Tg2576/Q170H mice, which harbor
comparable plaque loads (Figure 4D).
Collectively, these findings suggest that
ADAM10 activity affects not only the
plaque load but plaque morphology
as well.In conjunction with senile neuritic plaques, reactive gliosis is
one of the key pathological markers in AD brains (Simpson
et al., 2010). Compared to nontransgenic control, 18- to 20-
month-old Tg2576 mice showed robust increases in microglia
and astrocyte activation. The number of Iba1-positive microglia
was dramatically increased in association with Congo red-
stained neuritic plaques (Figures 5A and 5B), and GFAP-
expressing hypertrophic astrocytes became widespread in the
cortex (Figures 5C and 5D). Glial cell activation was enhanced
in Tg2576/DN mouse brains but barely detectable in Tg2576/
WT mice. Tg2576/Q170H showed higher levels of gliosis than
Tg2576/WT. Overall, the levels of gliosis in Tg2576/ADAM10
brains were correlated well with those of neuritic plaques. In
ADAM10 single-transgenic mice, we found no notable change
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Figure 6. ADAM10 Regulates Proliferation
and Differentiation of Neural Progenitor
Cells and Dendritic Development of Imma-
ture Neurons in Hippocampus
(A) Immunohistochemical staining for BrdU in the
dentate gyrus of nontransgenic, WT, Q170H, and
DN ADAM10 transgenic mice. Area between dots
and dashed lines is granular cell layer in hippo-
campus. Black dots (arrows) indicate BrdU-
positive neural progenitor cells (NPCs). Scale bar
represents 100 mm.
(B) Counts of BrdU-positive proliferating cells in
dentate gyrus at 1 day after BrdU injection.
Analyzed mice number: n = 6–7. *p < 0.05, **p <
0.01 versus ADAM10-WT (one-way ANOVA and
Tukey’s test).
(C) Percentile of BrdU-positive cells costained with
either NeuN or GFAP, or neither of the two cell
markers in each mouse group at 2 weeks after
BrdU injection. n = 6–7. *p < 0.05 versus ADAM10-
WT (one-way ANOVA and Tukey’s test).
(D) Photographs of dentate gyrus stained with
doublecortin (DCX). Most cell bodies of the DCX-
positive immature neurons were located in the
subgranular cell layer.
(E) High magnification of DCX-stained neurons in
dentate gyrus. Arrow, dendrite projecting; arrow-
head, tangential immature neurons.
(F) Counts of DCX-positive cells in dentate gyrus.
n = 6–7.
(G) Counts of dendrite-projecting DCX-positive
cells. *p < 0.05, **p < 0.01, ***p < 0.001 versus
ADAM10-WT; #p < 0.05, ##p < 0.01 versus non-
transgenic control (one-way ANOVA and Tukey’s
test). Values are mean ± SEM. See also Figure S5.
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ADAM10 Mutations Increase b-Amyloid Accumulationin glial cell activation (Figures S4A and S4B). Taken together,
these results suggest that nonamyloidogenic processing of
APP by ADAM10 reduces reactive gliosis in AD pathogenesis.Neuron 80, 385–401,Decreased ADAM10 Activity
Significantly Reduces Adult
Hippocampal Neurogenesis
To further examine the physiological con-
sequences of reduced ADAM10 activity
caused by the two LOAD mutations, we
tested for effects of WT versus mutant
ADAM10 on adult hippocampal neuro-
genesis. Recent studies have revealed
that application of sAPPa increases the
proliferation of neural progenitor cells
(NPCs) in vitro and in vivo (Caille´ et al.,
2004; Demars et al., 2011) and impair-
ments in hippocampal neurogenesis
have been linked to cognitive deficits in
AD (Zhao et al., 2008). Proliferation of
NPCs was analyzed by the incorporation
of BrdU, a nucleotide analog, into newly
born cells in the hippocampus. One day
after intraperitoneal injection of BrdU,
the number of BrdU-positive cells wassignificantly increased (48%) in the dendate gyrus of 4-month-
old ADAM10-WT transgenicmice as compared to nontransgenic
controls (Figures 6A and 6B). In contrast, in the Q170H and DNOctober 16, 2013 ª2013 Elsevier Inc. 393
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ADAM10 Mutations Increase b-Amyloid AccumulationADAM10 mice, the proliferation of NPCs remained at levels
similar to those of the control nontransgenic mice. The level of
NPC proliferation in ADAM10-R181G mice was similar
compared to that of Q170H mice (data not shown). The effect
of ADAM10 on differentiation of the NPCs was measured at
2 weeks after BrdU injection. Triple labeling of brain sections
with anti-BrdU antibody combined with antibodies for neuronal
(NeuN) and glial lineages (GFAP) revealed a 49% increase in
NPC differentiation into neurons in the ADAM10-WT mice as
compared to nontransgenic controls (Figures 6C and S5A). The
fraction of BrdU+:NeuN+ cells was modestly increased in
ADAM10-Q170H mice; however, the degree of increase was
lower than that of ADAM10-WT mice. Only a minor fraction
(<10%) of BrdU+ cells were colabeled with GFAP, and no signif-
icant differences were detected among the different mouse
groups for the glial differentiation. Together, these results indi-
cate that ADAM10 activity regulates the proliferation of NPCs
and their differentiation into neurons in adult hippocampus.
Moreover, the ADAM10 Q170H and DN mutations inhibited the
proliferation and differentiation of NPCs in adult brains.
The impact of ADAM10 expression was further examined for
potential effects on the dendritic development of the newborn
neurons in hippocampus. Immunostaining of brain sections
withdoublecortin (DCX), amarker for immatureneurons, revealed
that most of DCX-positive neurons in subgranular cell layer of
nontransgenic, ADAM10-WT, and -Q170H transgenic mice
project dendrites into or beyond the granular cell layer (projecting
DCX+ neurons; Figures 6D and 6E). However, in ADAM10-DN
mice, the length of dendrite inDCX-positive neuronwasmarkedly
decreased and many of the immature neurons were found
without dendrites in the subgranular cell layer (tangential DCX+
neurons). Both total DCX-positive and projecting DCX-positive
immature neurons are significantly elevated in ADAM10-WT
but reduced in ADAM10-DN mice (Figures 6F and 6G). In the
LOAD ADAM10-Q170H mice, which exhibit attenuated a-secre-
tase activity, the number of dendrite-projecting immature neu-
rons was significantly lower than that of ADAM10-WT.
To test for effects of APP processing on the regulation of hip-
pocampal neurogenesis, we measured levels of sAPPa and
sAPPb in the TBS-soluble fraction of hippocampal lysates.
Similar to the whole-brain lysates, WB analysis revealed an
elevated ratio of sAPPa/sAPPb in the hippocampus of
ADAM10-WT mice compared to that of nontransgenic or the
LOAD mutant ADAM10 mice (Figure S5B). However, no differ-
ence in the expression level and pattern of Notch1, a major
ADAM10 substrate contributing to embryonic neurogenesis,
was observed in the adult hippocampus among nontransgenic,
WT, and mutant ADAM10 transgenic mice (Figures S5C and
S5D). Taken together, these findings support that ADAM10
activity is tightly linked to the regulation of hippocampal neuro-
genesis and that the LOAD and DN mutations impair the neuro-
genic activity of ADAM10 in adult brain.
The LOAD Mutations Do Not Alter the Cellular
Trafficking of ADAM10 but Impair the Molecular
Chaperone Function of the Prodomain
The prodomain in the ADAM family proteins serves to ensure
correct protein folding and maintain the enzyme in a latent394 Neuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc.form (Anders et al., 2001). While the majority of cleaved
prodomain is readily degraded after liberation, under certain
conditions, the released prodomain remains and binds to the
mature enzyme (Moss et al., 2007), suggesting that it may
have a biological function following the cleavage. To determine
the underlying mechanism responsible for the attenuated
a-secretase activity by the prodomain mutations, we first
attempted to measure the level of liberated ADAM10 prodo-
main in mouse brains. However, immunoprecipitation followed
by WB analysis using a combination of antibodies targeting the
ADAM10 prodomain and cytosolic domain revealed that the
cleaved ADAM10 prodomain is undetectable (Figures 7A–7D).
These results suggest that the liberated ADAM10 prodomain
is rapidly degraded following cleavage in brain and that the
impact of the liberated prodomain on ADAM10 enzyme activity
is likely to be minimal. This also implies that the ADAM10
LOAD mutations may affect the prodomain function prior to
its liberation.
Next, we asked whether the prodomain mutations interfere
with the cellular trafficking of ADAM10. Previously, it has
been shown that the introduction of an artificial mutation
(Leu73Pro) in the ADAM12 prodomain results in the complete
retention of the enzyme in ER (Cao et al., 2002). Sucrose
gradient fractionation of brain lysates revealed that the
mature forms of ADAM10 and APP are enriched in lipid raft
fractions, where ectodomain shedding of ADAM10 itself and
a-secretase cleavage of APP mainly occur (Figure 7E). How-
ever, neither the prodomain LOAD mutations nor DN muta-
tions altered the cellular trafficking of ADAM10 and APP to
ER and lipid rafts. Surface biotinylation of primary cortical
neurons derived from ADAM10 transgenic mouse embryos
also indicated that the Q170H prodomain mutation did not
change the trafficking of the enzyme to the plasma membrane
(Figures 7F and 7G), a major location responsible for APP
cleavage by a-secretase. We also examined whether the pro-
domain mutations affect ADAM10 trafficking to the synapse,
in which the activity of the metalloprotease is regulated by
synapse-associated protein-97 (SAP-97) (Marcello et al.,
2007). As shown in Figure 7H, compared to the whole-brain
homogenates, the levels of both APP and APP-CTFa were
elevated in synaptosomal fraction and LOAD mutations
decreased APP-CTFa levels. However, ADAM10 levels at the
synapse were not changed by the prodomain mutations.
Together, these results suggest that the attenuated a-secretase
cleavage of APP by the LOAD mutations is not caused by
altered ADAM10 trafficking.
We next tested whether the LOAD ADAM10 mutations affect
the prodomain chaperone function. Previous studies have
shown that addition of a prodomain in trans to a prodomain-
deleted enzyme enables the completion of protein folding and
restores the enzyme activity for many types of proteases,
including ADAM10 (Anders et al., 2001; Cao et al., 2000).
Thus, we asked whether the ADAM10 prodomain in trans
affects the activity of prodomain-deleted ADAM10 (ADAM10D
pro). We also tested whether the two prodomain mutations
affect the chaperone activity of ADAM10 prodomain as com-
pared to WT. To this end, neuroblastoma H4 cells stably over-
expressing APP were transfected with either ADAM10Dpro
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Figure 7. Effects of ADAM10 LOAD Prodo-
main Mutations on Cellular Trafficking of
ADAM10
(A and B) Total brain lysates from each genotype of
ADAM10 transgenic mice were immunoprecipi-
tated with an antibody targeting ADAM10 cyto-
plasmic domain (CD), followed by WB with
anti-ADAM10-CD (A) or anti-ADAM10-prodomain
(PD) (B) antibodies. Similar results with (B) were
obtained by immunoprecipitation with anti-
ADAM10-PD antibody followed by WB with
either anti-ADAM10-CD or anti-ADAM10-PD anti-
bodies. Empty arrows indicate the position of
corresponding ADAM10 or ADAM10 cleavage
products. *, IgG heavy chain. Straight vertical lines
are inserted to mark two separate parts in the
same blot.
(C and D) WB analysis of brain lysates from
ADAM10-WT or nontransgenic mice with anti-
ADAM10 prodomain (25 kDa) antibody (C) and
HEK293 cell lysates from HA-tagged ADAM10
prodomain transfected cultures with anti-
ADAM10-prodomain or anti-HA antibodies (D).
#, nonspecific band.
(E) Mouse brain homogenates were separated by
ultracentrifugation in discontinuous sucrose gra-
dients. Mature forms of ADAM10 (large arrow, left),
APP (large arrow, right), and their CTFs are en-
riched in lipid raft fractions (fraction 4 and 5). Both
proADAM10 (small arrow, left) and immature APP
(small arrow, right) are enriched in ER. Calreticulin
and flotillin were used as cellular markers for ER
and lipid raft, respectively. *, nonspecific band.
(F) Primary cortical neurons (DIV13) derived from
nontransgenic, ADAM10-WT, or -Q170H trans-
genic mouse embryos were biotinylated to
measure ADAM10 levels in plasma membrane
(right). Actin is a negative control for surface bio-
tinylation.
(G) Densitometric quantification of total and sur-
face ADAM10 levels in primary neurons. n = 3.
Values are mean ± SEM.
(H) Synaptosome and postsynaptic density (PSD)
were isolated by sequential centrifugations of
mouse brain homogenates. Amount of proteins
loaded per lane: 15 mg for brain homogenates or
synaptosome fraction, and 5 mg for PSD fraction.
Synaptophysin and PSD95 were probed as pre-
and postsynaptic markers, respectively.
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ADAM10 Mutations Increase b-Amyloid Accumulationalone or in combination with ADAM10 prodomain constructs
expressing WT, Q170H, or R181G forms of ADAM10. Forty-
eight hours after transfection, the cells were harvested and
analyzed for APP and ADAM10 processing. While WT prodo-
main in trans dramatically increased the activity of prodo-
main-deleted ADAM10 (as evidenced by increased levels of
APP-CTFa), the ADAM10 prodomain harboring either Q170H
or R181G mutations failed to restore the enzyme activity of
ADAM10 (Figures 8A and 8B). These results suggest that the
LOAD mutations impair the chaperone function of ADAM10
prodomain.DISCUSSION
Although upregulation of a-secretase activity has been pro-
posed previously as a potential therapeutic strategy for AD by
precluding the generation of Ab (Donmez et al., 2010; Fahrenholz
and Postina, 2006), no genetic variants supporting this premise
had been reported until our recent finding of the two ADAM10
prodomain mutations, Q170H and R181G, in several LOAD
families (Kim et al., 2009). To investigate the potential pathogenic
effects of these LOAD mutations in vivo, in the current study, we
generated transgenic mice expressing human ADAM10: WT,Neuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc. 395
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Figure 8. Molecular Chaperone Function of ADAM10 Prodomain Is Compromised by ADAM10 LOAD Prodomain Mutations
(A) H4 cells were transfected with prodomain deletion cDNA construct (ADAM10DPro) alone or in combination with ADAM10 prodomain cDNA (WT, Q170H, or
R181G form). GFP and empty pCDNA3.1 (mock) vectors were used to adjust total transfected DNA amounts (800 ng). Cells were harvested and analyzed for APP
(A8717) and ADAM10 expression (anti-HA) 48 hr after transfection.
(B) Quantification of APP-CTFa level in transfected H4 cells. Results are combined from three independent transfection experiments. n = 5. **p < 0.01, ***p < 0.001
versus ADAM10DPro + WT prodomain group (one-way ANOVA and Tukey’s test). Values are mean ± SEM.
(C) Schematic model for attenuated a-secretase activity by the ADAM10 prodomain mutations. Green and yellow represent prodomain and the rest of ADAM10
domain, respectively. Red depicts LOAD mutation within the prodomain.
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ADAM10 Mutations Increase b-Amyloid Accumulationeach prodomain LOAD mutation, and an artificial dominant-
negative mutation. The impact of the mutations on AD pathology
was assessed by crossing these ADAM10 mice with the Tg2576
AD mouse model.
Several important insights have emerged from these efforts
(Figure 8C). First, we found that the two LOAD mutations dimin-
ished a-secretase activity of ADAM10 and shifted APP process-
ing toward b-secretase-mediated cleavage. The ectodomain
shedding of ADAM10 itself was also dramatically attenuated
by the prodomain mutations. Second, we showed that the
ADAM10 mutations elevate Ab levels, plaque load, and reactive
gliosis in Tg2576 AD mice. Plaque morphology (diffuse versus
neuritic) was also affected by ADAM10 activity. Third, we
demonstrated that ADAM10 plays critical roles in adult hippo-
campal neurogenesis and the LOAD and DN mutations impair
this activity. Finally, with regard to the pathogenic mechanism,
we showed that both LOADADAM10mutations impair molecular
chaperone function of the ADAM10 prodomain. Beyond the four
established AD genes (APP, PSEN1, PSEN2, and APOE), this
report documents additional AD-associated pathogenic gene
mutations in vivo. The evidence presented here support that
ADAM10 is a bona fide AD susceptibility gene that can harbor
rare mutations causing LOAD.
ADAM10 Transgenic Mice and ADAM10 Processing
To test for the in vivo effects of the LOAD ADAM10 prodomain
mutations, we compared transgenic mice expressing either WT
or mutant forms of human ADAM10 in the brain. To reduce
potential bias stemming from individual mouse line-dependent
variables (e.g., different expression level), we analyzed all F1
mice and their progeny from different ADAM10 genotypes
(minimum three mouse lines per genotype). Two lines from
each genotype, all of which possess ADAM10 expression level
comparable to a control line (WT-58), were selected for further
analysis of APP processing. Immunoblot analysis of the trans-
genic mouse brains confirmed that the pattern of ADAM10 and
APP processing are dependent on the ADAM10 genotype, not
individual mouse lines (Figure 1).
To address the impact of the ADAM10 mutations on brain
pathology, we chose Tg2576 as an AD mouse model. These
mice overexpress human APP harboring the Swedish mutation
at the b-secretase cleavage site, under the expression control
of prion protein promoter sequence, in B6/SJL hybrid back-
ground. Thus, to avoid the influence on phenotype expression
in Tg2576/ADAM10 double-transgenic mice, particularly with re-
gard to Ab generation and deposition, we generated ADAM10
transgenic mice by employing the same expression promoter
and genetic background as in the Tg2576 mice.
To account for potential incomplete penetrance of the prodo-
main mutations, akin to effects on AD pathology reported for
transgenic mice expressing the ε4 risk allele of APOE, we
included an artificial DN mutation of ADAM10 (E384A), as a pos-
itive control to simulate a fully penetrant mutation. The E384ADN
mutationwas originally reported inDrosophila at the zinc-binding
catalytic site of the enzyme, marking the protease as an inactive
form (Pan and Rubin, 1997). However, in vivo overexpression of
the defective protease resulted in dominant-negative signaling
pattern related to the enzyme activity, probably by competingwith endogenous ADAM10 for its substrates and auxiliary factors
essential for the enzyme activity (Lammich et al., 1999; Pan and
Rubin, 1997). In this study, we also observed dramatic effects of
the artificial dominant-negative mutant form of ADAM10 on APP
processing, Ab accumulation, and hippocampal neurogenesis.
Meanwhile, the two LOAD mutations in the ADAM10 prodomain
exerted significant but less dramatic effects on ADAM10 activity
in brain. Although complete ablation of endogenous mouse
ADAM10 results in lethal developmental defects in brain (Hart-
mann et al., 2002; Jorissen et al., 2010), partial reduction of the
endogenous metalloprotease activity by the overexpression of
ADAM10-DN form did not produce any notable abnormality in
brain morphology up to 24 months old (data not shown). All the
ADAM10 transgenic mouse lines used in this study maintain
endogenous mouse ADAM10. Therefore, the impact of different
ADAM10 genotypes (WT, Q170H, R181G, and DN) on substrate
(e.g., APP) processing would probably be affected by the pres-
ence of the wild-type form of endogenous mouse ADAM10.
However, we deemed it necessary to retain the endogenous
ADAM10 to prevent potential developmental defects that might
have occurred in its absence.
The evidence that the two ADAM10 LOADmutations attenuate
enzyme activity was derived from our observation of reduced
ectodomain shedding of ADAM10 itself. In agreement with the
recent findings from in vitro studies of ADAM10 and other
ADAM protease processing (Gaultier et al., 2002; Kang et al.,
2002; Taylor et al., 2009; Tousseyn et al., 2009), the complete
absence of ADAM10-CTF in all the DN mouse lines (Figures 1
and S1) suggest that ADAM10 activity regulates its own ectodo-
main shedding at the cysteine-rich domain. Structurally, the
C-shaped conformation of the metalloprotease family proteins
enables the protease domain to come in close proximity to the
cysteine-rich domain (Takeda et al., 2006). This unique structural
characteristic also supports the possibility of an autocatalytic
mechanism in ADAM10 ectodomain shedding. The ADAM10
LOADmutations in the prodomain may interfere with the ectodo-
main shedding by decreasing either the enzyme activity (prote-
ase domain) or substrate accessibility (cysteine-rich domain) of
ADAM10.
Competition between a- and b-Secretases on APP
Processing and Ab Generation
In the ADAM10 transgenic mice, the prodomain and catalytic-
site mutations decrease a-site cleavage of APP (less APP-
CTFa). Notably, reduced a-secretase activity was accompanied
by an increase in b-secretase processing of APP (higher levels of
APP-CTFb, sAPPb, and Ab). Concordantly, amissensemutation,
which was recently found in an early-onset dementia family pre-
cisely at the APP a-secretase cleavage site (K16N), led to a
decrease in APP-CTFa coupled with increases in levels of
APP-CTFb and Ab (Kaden et al., 2012). Inverse effects have
been reported in mice with altered b-secretase gene expression.
BACE1 KOmice produced elevated APP-CTFa (Luo et al., 2001),
and BACE1 transgenic mice revealed reduced APP-CTFa with
increased APP-CTFb and sAPPb (Lee et al., 2005). Although
several cell-based studies produced inconsistent results with
regard to these alternative cleavages (Colombo et al., 2012),
studies using genetically modifiedmice have consistently shownNeuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc. 397
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APP processing in the brain (Lee et al., 2005; Luo et al., 2001;
Postina et al., 2004).
Remarkably, while ADAM10-WT overexpression in Tg2576
mice decreased 35% of Ab levels at 3 months old, the impact
was dramatically magnified at 12 months, at which point Ab40
and Ab42 levels were decreased by more than 99% in the
ADAM10-WT mice (Figure 3). LOAD mutant forms of ADAM10,
which possess attenuated a-secretase activity (60%–70% of
WT), did not produce notable decreases in Ab levels in
3-month-old double-transgenic mice. However, Ab levels were
dramatically downregulated (95%) in the brains of 12-month-
old double transgenics, as compared to Tg2576 control. The
robust decrease in Ab plaque load was maintained up to 18 to
20 months old (Figure 4). This profound impact on plaque load
by ADAM10 in older brains is consistent with a previous report
that employed transgenic mice overexpressing bovine
ADAM10 and human APP London mutation (Postina et al.,
2004). In addition to the potential direct cleavage of Ab by
ADAM10 (Lammich et al., 1999), this increased effect in older
mice might be the result of accumulated production and deposi-
tion of excess Ab in brains. As the half-life of Ab in brains is only
2 hr (Cirrito et al., 2003), changes in Ab generation rate would
greatly affect the accumulation and deposition of Ab over several
months in the brains of APPswe-overexpressing Tg2576
mice. Aging-enhanced Ab accumulation was also reported in
Bace1+/+ mice compared to Bace1+/ mice (McConlogue
et al., 2007). Collectively, these findings suggest that modest
modulation of a- or b-secretase activity for extended time period
can have a profound impact on Ab pathology in aged brain.
Beyond the level of plaque load, ADAM10 activity also affected
the morphology of Ab plaque. While Tg2576/DN double-trans-
genic mice had more neuritic plaques with compact cores
(versus Tg2576), most plaques found in the double-transgenic
mice overexpressing WT or Q170H displayed irregular diffuse
morphology. Neuritic plaques are known to bemore tightly asso-
ciated with AD pathogenesis than diffuse plaque. For example,
fibrillar core-containing neuritic plaques are predominant in AD
brains, whereas diffuse plaques are more frequent in nonde-
mented elderly (Selkoe, 2001). Furthermore, neuritic, but not
diffuse, plaques are associated with pathological phenotypes
of the disease, including dystrophic neurites, activated micro-
glia, and reactive astrocytes (Figure 5). While further studies
are warranted to delineate the mechanism underlying the
observed differences in plaque morphology, our findings sug-
gest that enhanced ADAM10 activity may lessen Ab pathology
not only by decreasing plaque load but also by affecting plaque
morphology.
Currently, it is unclear how the two secreted APP ectodo-
mains, sAPPa and sAPPb, engender different effects—neurotro-
phic versus neurodegenerative—on neurons. Interestingly, a
35 kDa fragment derived from sAPPb has been demonstrated
to bind the cell surface death receptor DR6 and trigger axonal
degeneration in neurons (Nikolaev et al., 2009). In addition to
the extra 16 amino acids at the C terminus of sAPPa, the differ-
ence in where these ectodomains are generated, cell surface for
sAPPa, and endosome for sAPPb may play a key role in deter-
mining their distinct biological functions. At the cell surface,398 Neuron 80, 385–401, October 16, 2013 ª2013 Elsevier Inc.APP can be present as a dimer in cis or trans formation (Wang
and Ha, 2004). Structural and imaging studies have shown that
liberated sAPPa can bind as a ligand to APP at cell surface
and disrupt APP dimer complex to exert its neuroprotective
effect (Gralle et al., 2009; Wang and Ha, 2004). Therefore, it is
interesting to speculate that ADAM10 cleavage of APP may shift
the complex formation toward neurotrophic APP-sAPPa (or its
cleavage derivatives) versus APP-APP dimerization at the cell
surface.
Hippocampal Neurogenesis and Molecular Chaperone
Function of ADAM10 Prodomain
Accumulating evidence shows that elevated hippocampal neuro-
genesis improves memory function (Zhao et al., 2008) and that
downregulation of hippocampal neurogenesis is associated
with cognitive impairments in AD (Choi et al., 2008). Notably,
adult neurogenesis has been reported to be affected by all three
early-onset familial AD genes, APP, PSEN1, and PSEN2, and by
Ab in ADmousemodels (Mu andGage, 2011), suggesting its tight
link to the etiology and pathogenesis of the disease. With regard
to ADAM10, Bell and colleagues reported that moderate expres-
sion of bovine ADAM10 or exogenous infusion of sAPPa in the
cortex increases presynaptic bouton density, indicative of neuro-
trophic effects of ADAM10 on cortical synaptogenesis (Bell
et al., 2008). Additionally, lateral ventricular injection of sAPPa
increased the proliferation of NPCs in the subventricular zone,
another neurogenic niche in mouse brain (Caille´ et al., 2004).
All ADAM family proteins contain an N-terminal prodomain,
which acts to chaperone and ensure the proper folding of this
family of metalloproteases. Our results show that the cleaved
ADAM10 prodomain appears to be quickly degraded in the brain
and that cellular trafficking of ADAM10 is not affected by the pro-
domain mutations. Interestingly, while the prodomain may be
degraded, it may still have the ability to affect themature enzyme
via its intramolecular chaperone function. This phenomenon,
dubbed ‘‘protein memory,’’ was reported in mutant subtilysin,
a serine protease harboring a mutation in its prodomain (Shinde
et al., 1997). The point mutation yielded mature subtilysin that
had a different structure and activity via ‘‘structural imprinting’’
during protein folding (Shinde et al., 1997). Improperly chaper-
oned, mis-folded proteases can be restructured and become
active by ectopic expression of WT prodomain (Cao et al.,
2000). In our mammalian cell-based studies, WT but not mutant
ADAM10 prodomain rescued the a-secretase activity of inactive
ADAM10 expressed from a prodomain-deleted cDNA construct.
This indicates impairment of the chaperone function of the pro-
domain by the LOAD mutations (Figure 8C). In further support
of this conclusion, secondary structure predictions showed
that the only a-helix in the prodomain can be terminated by the
R181G mutation (McGuffin et al., 2000). To date, a few patho-
genic amino acid substitutions, which are not present in the
mature forms, have been associated with diseases. But to our
knowledge, the two LOAD ADAM10 mutations are the first to
be associated with the etiology of any disease by impairing the
intramolecular chaperone function of a prodomain.
Increased ADAM10 a-secretase activity could potentially
be achieved by multiple different mechanisms, including the
activation of ADAM10 gene transcription by retinoic acid, the
Neuron
ADAM10 Mutations Increase b-Amyloid Accumulationinhibition of natural ADAM10 inhibitors (e.g., TIMPs, tissue inhib-
itor of metalloproteases), and themodulation of ADAM10 cellular
trafficking (Lichtenthaler, 2011). While dozens of proteins have
been reported as ADAM10 substrates (Pruessmeyer and
Ludwig, 2009), only a handful are related to brain and neuronal
function. Moreover, in contrast to the ADAM10 knockdown,
our data and a previous report by Postina et al. (2004) support
that modest elevation of ADAM10 is relatively well tolerated
and does not affect Notch1 signaling in adult brain. Therefore,
while a careful evaluation will be essential to assess the potential
unwanted side effects elicited by chronic ADAM10 activation,
our results suggest that brain-specific a-secretase-based ther-
apy could be a useful alternative or combination therapy with
current AD therapeutics, e.g., targeting of b- or g-secretases.
For past two decades, more than 1,400 genetic studies have
been carried out to elucidate the genetic loci influencing risk
for AD (Bertram et al., 2010). Most recently, a high priority has
been placed on identifying rare functional variants with high
penetrance on disease risk by resequencing for inherited dis-
eases, including AD (Pottier et al., 2012). In this study, we have
presented in vivo functional analyses of two highly penetrant
LOAD mutations in ADAM10, which we originally found by rese-
quencing this gene in follow up to the observation of genetic
association of several ADAM10 SNPs with AD (Kim et al.,
2009). The multiple in vivo functional effects of these ADAM10
prodomain LOAD mutations presented here suggest that upre-
gulation of ADAM10 a-secretase activity may be beneficial for
AD by two distinct but functionally closely related biological
mechanisms: (1) decrease of neurotoxic Ab accumulation by
nonamyloidogenic cleavage of APP in brain and (2) upregulation
of neurogenesis in hippocampus. A tractable ADAM10-specific
activator possessing these two neuroprotective properties could
potentially be used as a potent therapeutic intervention for treat-
ing and preventing AD.
EXPERIMENTAL PROCEDURES
Procedures are described in detail in Supplemental Experimental Procedures.
Detailed methods for mouse brain lysate preparation, western blotting and
immunoprecipitation, sAPPa and sAPPb ELISA, primary cortical neurons
and surface biotinylation, analysis of reactive gliosis, ADAM10 prodomain
chaperone activity assay, cerebrospinal fluid (CSF) collection, sucrose
gradient fractionation, and synaptosome and postsynaptic density isolation
are described in Supplemental Experimental Procedures.
ADAM10 Transgenic Mice
ADAM10 transgenic mice were generated by the injection of human ADAM10
cDNA (2.23 kb) of WT, Q170H, R181G, and E384A mutant forms into embryos
derived from B6SJLF1 female mice. Except one ADAM10-DNmouse line (DN-
120), which was30% smaller in size from birth, all other ADAM10 transgenic
mice were inconspicuous in morphology, breeding, and daily handling,
compared to nontransgenic control mice. Immunohistochemical analysis
using anti-HA antibodies showed that human ADAM10 is highly expressed
in the cortex and hippocampus of transgenic mice. All animal generation,
husbandry, and experimental procedures were approved by the MGH Sub-
committee on Research Animal Care (SRAC). See Supplemental Experimental
Procedures for details.
Ab ELISA and Plaque Load Analysis
TBS brain lysates were centrifuged at 100,000 3 g for 1 hr and the superna-
tants were saved for ‘‘soluble Ab’’ measurements. Pellets were resuspendedand further homogenized in 70% formic acid, followed by centrifugation at
100,0003 g. Formic acid supernatants are neutralized with 1 M Tris for ‘‘insol-
uble Ab’’ analysis. The amounts of soluble and insoluble Ab40 and Ab42 were
determined by sandwich ELISA using commercially available kits (Wako). For
Ab plaque load analysis, 4% paraformaldehyde-fixed brain sections were
probed with anti-Ab antibody and DAPI. For 12-month-old brain sections,
the numbers of Ab plaque in cortex and hippocampus were counted without
the genotype information. For 18- to 20-month-old mice, the area covered
by Ab was analyzed by ImageJ. The numbers of Thioflavin S-stained neuritic
plaques were also analyzed by ImageJ. See Supplemental Experimental Pro-
cedures for details.
NPCs Proliferation and Differentiation Analysis
Mice were injected once daily with BrdU (100 mg/kg, i.p.) for 3 consecutive
days. Half of the mice in each group were sacrificed 1 day after the final injec-
tion of BrdU to identify proliferating neural progenitor cells (NPCs). The remain-
ing mice were sacrificed 2 weeks after the final injection of BrdU to determine
survival and neuronal differentiation of the newborn cells. See Supplemental
Experimental Procedures for details.
Statistical Analyses
Data are presented as the mean ± SEM. Comparisons between two groups
were performed with the independent-samples t test, and those among
more than two groups were performed with ANOVA followed by Tukey’s
test. All analyses were performed with SPSS version 12.0. p value of <0.05
was considered statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.neuron.2013.08.035.
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